Potassium channel blockers as immunosuppressants

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Recent advances in the biology of potassium channels have raised their profile as therapeutic targets for immunosuppression. Selective blockade of the intermediate-conductance calcium-activated potassium channel KCa3.1, and in particular, the voltage-gated potassium channel, Kv1.3 holds great promise in the modulation of different subsets of inflammatory T cells and B cells involved in the pathogenesis of autoimmune and inflammatory diseases. Relatively few selective blockers of these channels have been discovered to date, but this situation is likely to change as these channels become increasingly prominent as tractable and selective therapeutic targets, and especially if they are clinically validated as immunosuppressive targets.

Original languageEnglish
Pages (from-to)1209-1220
Number of pages12
JournalExpert Opinion on Therapeutic Patents
Volume15
Issue number9
DOIs
Publication statusPublished - 1 Sep 2005
Externally publishedYes

Keywords

  • Experimental autoimmune encephalomyelitis (EAE)
  • IK
  • IKCa1
  • Immunosuppressant
  • Immunosuppression
  • KCa3.1
  • KCNA3
  • KNNC4
  • Kv1.3
  • Multiple sclerosis (MS)
  • Potassium channel blocker

Cite this

@article{8fb4f17aa7474728a5ca6d924a548b02,
title = "Potassium channel blockers as immunosuppressants",
abstract = "Recent advances in the biology of potassium channels have raised their profile as therapeutic targets for immunosuppression. Selective blockade of the intermediate-conductance calcium-activated potassium channel KCa3.1, and in particular, the voltage-gated potassium channel, Kv1.3 holds great promise in the modulation of different subsets of inflammatory T cells and B cells involved in the pathogenesis of autoimmune and inflammatory diseases. Relatively few selective blockers of these channels have been discovered to date, but this situation is likely to change as these channels become increasingly prominent as tractable and selective therapeutic targets, and especially if they are clinically validated as immunosuppressive targets.",
keywords = "Experimental autoimmune encephalomyelitis (EAE), IK, IKCa1, Immunosuppressant, Immunosuppression, KCa3.1, KCNA3, KNNC4, Kv1.3, Multiple sclerosis (MS), Potassium channel blocker",
author = "Bael, {Jonathan B.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1517/13543776.15.9.1209",
language = "English",
volume = "15",
pages = "1209--1220",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Taylor & Francis",
number = "9",

}

Potassium channel blockers as immunosuppressants. / Bael, Jonathan B.

In: Expert Opinion on Therapeutic Patents, Vol. 15, No. 9, 01.09.2005, p. 1209-1220.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Potassium channel blockers as immunosuppressants

AU - Bael, Jonathan B.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Recent advances in the biology of potassium channels have raised their profile as therapeutic targets for immunosuppression. Selective blockade of the intermediate-conductance calcium-activated potassium channel KCa3.1, and in particular, the voltage-gated potassium channel, Kv1.3 holds great promise in the modulation of different subsets of inflammatory T cells and B cells involved in the pathogenesis of autoimmune and inflammatory diseases. Relatively few selective blockers of these channels have been discovered to date, but this situation is likely to change as these channels become increasingly prominent as tractable and selective therapeutic targets, and especially if they are clinically validated as immunosuppressive targets.

AB - Recent advances in the biology of potassium channels have raised their profile as therapeutic targets for immunosuppression. Selective blockade of the intermediate-conductance calcium-activated potassium channel KCa3.1, and in particular, the voltage-gated potassium channel, Kv1.3 holds great promise in the modulation of different subsets of inflammatory T cells and B cells involved in the pathogenesis of autoimmune and inflammatory diseases. Relatively few selective blockers of these channels have been discovered to date, but this situation is likely to change as these channels become increasingly prominent as tractable and selective therapeutic targets, and especially if they are clinically validated as immunosuppressive targets.

KW - Experimental autoimmune encephalomyelitis (EAE)

KW - IK

KW - IKCa1

KW - Immunosuppressant

KW - Immunosuppression

KW - KCa3.1

KW - KCNA3

KW - KNNC4

KW - Kv1.3

KW - Multiple sclerosis (MS)

KW - Potassium channel blocker

UR - http://www.scopus.com/inward/record.url?scp=25444432308&partnerID=8YFLogxK

U2 - 10.1517/13543776.15.9.1209

DO - 10.1517/13543776.15.9.1209

M3 - Review Article

VL - 15

SP - 1209

EP - 1220

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 9

ER -